The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches
Rhea-AI Summary
The Precision Peptide Company (CSE: BPC, OTCQB: PNGAF) announced receipt of its full production run of approximately 20,000 units of its BPC-157 transdermal patch, the company's lead product candidate. This commercial inventory follows a previously announced order and marks a transition from testing and formulation validation toward commercialization.
The Patch is manufactured in the United States and independently tested by a U.S. analytical laboratory. Each patch is formulated to deliver 2 mg of BPC-157, supported by third-party results confirming 95.5% chromatographic purity and a quantified dose of 2.02 mg per patch. The company plans initial commercial release through its website.
Positive
- 20,000 BPC-157 patches received as commercial production run
- Independent U.S. lab confirmed 95.5% purity, above ≥95% industry benchmark
- Each patch tested with a quantified 2.02 mg BPC-157 dose
- Transition from testing and validation toward commercialization of lead product
- Patches are manufactured and tested in the United States
Negative
- None.
News Market Reaction – PNGAF
In the Jul 14 session, PNGAF declined 1.54%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Highlights
- Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate
- Patches are manufactured and independently tested in the United States
- Marks the Company's transition from testing to commercialization
- Each patch delivers 2 mg of BPC-157, consistent with the
95.5% purity and 2.02 mg dose
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the "Patch"), the Company's lead product candidate. The arrival of this commercial inventory follows the Company's previously announced order (previously announced here) and represents a key step in the Company's transition from testing and formulation validation to commercialization.
The Patch is proudly manufactured in the United States and was independently tested by a U.S. analytical laboratory. Each Patch is formulated to deliver 2 mg of BPC-157, consistent with the third-party test results reported in the Company's previous news release, which confirmed
With commercial inventory now in hand, the Company is positioned to proceed toward the initial commercial release of the Patch through The Precision Peptide Company website.
Pratap Sandhu, CEO of The Precision Peptide Company, commented:
"We are proud that our patches are made and tested right here in the U.S. That reflects the standard we've set for ourselves and for our customers. We ordered 20,000 units and they've now arrived, which moves us into fulfillment as we prepare to begin selling through our website."
About The Precision Peptide Company
The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the Company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.
For more information, visit: www.precisionpeptidecompany.com
Company Contact
Pratap Sandhu CEO, Corporate Secretary and Director
pratap@precisionpeptidecompany.com
+1 (604) 765-8069
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, including, without limitation, statements relating to the Company's plans to commercially release the Patch through its website, the Company's transition from testing and formulation validation to commercialization, and the anticipated distribution of the Patch across North America. Forward-looking information is based on the opinions and estimates of management at the date such information is provided and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those expressed or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: regulatory approvals and compliance requirements; market acceptance of the Company's products; competition in the wellness and peptide industry; the Company's ability to successfully commercialize its products; supply chain risks; and general economic and market conditions. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. The Company does not undertake any obligation to update forward-looking information, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305067